The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Cancer Drugs in the United States: Justum Pretium—The Just Price
Open accessAbstract
Baker Institute for Public Policy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Projections of the cost of cancer care in the United States: 2010–2020
Mariotto, A. B., Robin Yabroff, K., Shao, Y., Feuer, E. J., & Brown, M. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq495 · Cited by 2,657
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S.-S., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9847 · Cited by 899
The truth about the drug companies: how they deceive us and what to do about it
(2005) · Choice Reviews Online · doi:10.5860/choice.42-5297 · Cited by 885
Medical Bankruptcy in the United States, 2007: Results of a National Study
Himmelstein, D. U., Thorne, D., Warren, E., & Woolhandler, S. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.04.012 · Cited by 805
Kantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376087 · Cited by 610
Self-citationKantarjian, H. M., Hochhaus, A., Saglio, G., De Souza, C., Flinn, I. W., Stenke, L., Goh, Y.-T., Rosti, G., Nakamae, H., Gallagher, N. J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70201-7 · Cited by 513
Self-citationThe Truth About Drug Companies: How They Deceive Us and What to Do About It.
Henderson, S. W. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000157547.41337.46 · Cited by 506
Escudier, B., Szczylik, C., Hutson, T. E., Demkow, T., Staehler, M., Rolland, F., Negrier, S., Laferriere, N., Scheuring, U. J., Cella, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3342 · Cited by 490
Bending the Cost Curve in Cancer Care
Smith, T. J., & Hillner, B. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1013826 · Cited by 391
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Bach, P. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmhpr0807774 · Cited by 390
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question
Fojo, T., & Grady, C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp177 · Cited by 349
Self-citationHuang, X., Cortes, J., & Kantarjian, H. (2012) · Cancer · doi:10.1002/cncr.26679 · Cited by 300
Self-citationDemythologizing the high costs of pharmaceutical research
Light, D. W., & Warburton, R. (2011) · BioSocieties · doi:10.1057/biosoc.2010.40 · Cited by 213
An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard
Lee, C. P., Chertow, G. M., & Zenios, S. A. (2009) · Value in Health · doi:10.1111/j.1524-4733.2008.00401.x · Cited by 196
Dilts, D. M., & Sandler, A. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0104 · Cited by 165
Elkin, E. B., & Bach, P. B. (2010) · JAMA · doi:10.1001/jama.2010.283 · Cited by 157
The $800 million pill: the truth behind the cost of new drugs
(2005) · Choice Reviews Online · doi:10.5860/choice.42-5898 · Cited by 135
Hillner, B. E., & Smith, T. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0534 · Cited by 121
Goozner, M. (2004) · University of California Press eBooks · doi:10.1525/9780520939288 · Cited by 120
Equipoise Lost: Ethics, Costs, and the Regulation of Cancer Clinical Research
Stewart, D. J., Whitney, S. N., & Kurzrock, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5404 · Cited by 109
Stewart, D. J., & Kurzrock, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9621 · Cited by 104
Steps and Time to Process Clinical Trials at the Cancer Therapy Evaluation Program
Dilts, D. M., Sandler, A. B., Cheng, S. K., Crites, J. S., Ferranti, L. B., Wu, A. Y., Finnigan, S. R., Friedman, S., Mooney, M., & Abrams, J. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9133 · Cited by 67
Dilts, D. M., Sandler, A. B., Cheng, S. K., Crites, J. S., Ferranti, L. B., Wu, A. Y., Gray, R. J., MacDonald, J., Marinucci, D. M., & Comis, R. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5060 · Cited by 56
Naing, A., Rodrigues, H. V., Hong, D. S., Fu, S., Falchook, G. S., Wheler, J. J., Tsimberidou, A. M., Wen, S., Fessahaye, S. N., Golden, E. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds130 · Cited by 47
The $64,000 question—What is a quality-adjusted life-year worth?
Rascati, K. L. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.07.002 · Cited by 30
Kantarjian, H. M., & O'Brien, S. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00190-1 · Cited by 17
Self-citationDALYs And QALYs In Developing Countries
Zárate, V. (2007) · Health Affairs · doi:10.1377/hlthaff.26.4.1197-a · Cited by 9
Cited by
Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival
Jemal, A., Ward, E. M., Johnson, C. J., Cronin, K. A., Ma, J., Ryerson, A. B., Mariotto, A., Lake, A. J., Wilson, R., Sherman, R. L., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx030 · Cited by 1,556
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Gut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970
Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A., & Aggarwal, A. (2017) · BMJ · doi:10.1136/bmj.j4530 · Cited by 599
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559
Metadata
- Authors
- Kantarjian, H. M., Fojo, T., Mathisen, M., & Zwelling, L. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-10-01
- Volume
- 31
- Issue
- 28
- Pages
- 3600-3604
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2135906122
- Cited by
- 284
- References
- 36
- FWCI
- 109.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.